JAN 05, 2016 03:13 PM PST

Prevent Ebola From Mutating, Prevent It From Returning

WRITTEN BY: Kara Marker
There’s no rest for the weary, and that includes researchers looking for a definitive cure and treatment plan for Ebola patients. Even though Guinea was declared free of the hemorrhagic disease just before ringing in the new year, the threat of the virus evolving to be more dangerous and evasive than before has kept scientists on the hunt for a final answer.

Ebola is caused by an RNA virus whose genome encodes proteins such as nucleoprotein, glycoprotein, and L protein that are all sealed in a viral envelope (Kenyon College). Although there currently are vaccines that target these vital structural proteins to prevent Ebola virus from infecting host cells, a few different strains of the deadly disease exist that vary enough in amino acid and nucleotide sequencing to make a general vaccine impossible to create.

To make matters worse, the Ebola virus also contains to potential to evolve, and this is what scientists from the Texas Biomedical Research Institute wanted to investigate in a new Journal of Virology publication.
 

 
"Any change in a genome can be neutral, negative, or positive to a virus," Anthony Griffiths, PhD, explained. "Interestingly, viruses appear to have evolved to have an optimal mutation rate. Increasing the mutation rate could produce a negative effect on the virus and serve as a valuable therapeutic tool."

Griffiths explained that they will not have to prevent Ebola from mutating all together, just stimulate enough stress to increase the mutation rate so viral cells are weakened and inviable.

"We found that Ebola virus had very limited ability to tolerate spontaneous changes in the genome,” he said.

They tested a drug for chronic hepatitis C, called ribavirin, to see if Ebola cells faltered like they predicted they would after meddling with the viral mutation rate. Ribavirin is a nucleoside inhibitor that prevents viruses from synthesizing RNA and viral mRNA capping (Merck). Although the team saw successful clinical trials in mice and monkey subjects, further studies are required to make ribavirin a substantial candidate for treating Ebola.
 
The fight against Ebola in Guinea

Source: Texas Biomedical Research Institute
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 21, 2018
Cell & Molecular Biology
NOV 21, 2018
Preventing the Wrong Cells From Forming in Organoids
Organoids are advancing research by providing scientists with a 3D model of a human organ. But are they what they seem?...
NOV 25, 2018
Microbiology
NOV 25, 2018
Researchers Learn How Hantavirus Infects Cells
First identified in 1993, hantavirus infections can cause dangerous and potentially deadly respiratory infections....
NOV 27, 2018
Immunology
NOV 27, 2018
A Genetic Switch During Inflammation
Microglia, CNS immune cells, change their genetic profile during different states of the inflammation spectrum...
DEC 04, 2018
Genetics & Genomics
DEC 04, 2018
The All-you-can-eat Gene?
Many people dream of being able to eat the foods they want without having to worry about weight gain. New research shows it may one day be possible....
DEC 10, 2018
Genetics & Genomics
DEC 10, 2018
Finding New Areas of the Human Genome to Explore
Scientists have found a new way to identify disease-causing genes....
DEC 26, 2018
Immunology
DEC 26, 2018
When the Immune System Makes a Mistake: Autoimmunity
A team from Scripps Research has found a molecular cause of a group of rare autoimmune disorders in which the immune system attacks the body's healthy cells....
Loading Comments...